{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:37:38Z","timestamp":1780447058901,"version":"3.54.1"},"reference-count":124,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cjca.2026.01.003","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:27:03Z","timestamp":1768202823000},"page":"982-1003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging Gene Therapies for Inherited Arrhythmia Syndromes"],"prefix":"10.1016","volume":"42","author":[{"given":"Luca","family":"Grisorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0268-6723","authenticated-orcid":false,"given":"Jason D.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2026.01.003_bib1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","article-title":"AAV-mediated gene therapy for research and therapeutic purposes","volume":"1","author":"Samulski","year":"2014","journal-title":"Annu Rev Virol"},{"key":"10.1016\/j.cjca.2026.01.003_bib2","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1161\/CIRCRESAHA.114.302331","article-title":"Adeno-associated virus vectors as therapeutic and investigational tools in the cardiovascular system","volume":"114","author":"Zacchigna","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2026.01.003_bib3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cjca.2026.01.003_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.r1548","article-title":"Duchenne gene therapy halted after three deaths and company U turn","volume":"390","author":"Taylor","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2026.01.003_bib6","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","article-title":"Unlocking the promise of mRNA therapeutics","volume":"40","author":"Rohner","year":"2022","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cjca.2026.01.003_bib7","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1093\/eurheartj\/ehac463","article-title":"Small noncoding RNA therapeutics for cardiovascular disease","volume":"43","author":"Shah","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.01.003_bib8","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","article-title":"Origins and mechanisms of miRNAs and siRNAs","volume":"136","author":"Carthew","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.cjca.2026.01.003_bib9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cjca.2026.01.003_bib10","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1161\/CIRCULATIONAHA.123.068111","article-title":"Antisense oligonucleotide therapy for calmodulinopathy","volume":"150","author":"Bortolin","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.003_bib11","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.ymthe.2020.12.023","article-title":"Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles","volume":"29","author":"Biscans","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.cjca.2026.01.003_bib12","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/eurheartj\/ehaa898","article-title":"Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human phase 1b randomized, double-blind, placebo-controlled study","volume":"42","author":"T\u00e4ubel","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.01.003_bib13","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/CIRCULATIONAHA.120.051836","article-title":"Suppression-replacement KCNQ1 gene therapy for type 1 long Qt Syndrome","volume":"143","author":"Dotzler","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.003_bib14","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cjca.2026.01.003_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav4523","article-title":"Intein-mediated protein trans-splicing expands adeno-associated virus transfer capacity in the retina","volume":"11","author":"Tornabene","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cjca.2026.01.003_bib16","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","article-title":"High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population","volume":"25","author":"Wagner","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2026.01.003_bib17","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41587-023-01915-4","article-title":"Genotoxic effects of base and prime editing in human hematopoietic stem cells","volume":"42","author":"Fiumara","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cjca.2026.01.003_bib18","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1038\/s41467-019-12449-2","article-title":"High levels of AAV vector integration into CRISPR-induced DNA breaks","volume":"10","author":"Hanlon","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.cjca.2026.01.003_bib19","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1038\/s41467-021-26830-7","article-title":"Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models","volume":"12","author":"Hakim","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.cjca.2026.01.003_bib20","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1016\/j.jacc.2020.12.073","article-title":"Precision medicine in catecholaminergic polymorphic ventricular tachycardia: JACC focus seminar 5\/5","volume":"77","author":"Priori","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2026.01.003_bib21","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3390\/biom13121693","article-title":"The structural-functional crosstalk of the calsequestrin system: insights and pathological implications","volume":"13","author":"Marabelli","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.cjca.2026.01.003_bib22","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.hrthm.2013.05.014","article-title":"HRS\/EHRA\/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013","volume":"10","author":"Priori","year":"2013","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2026.01.003_bib23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrcardio.2012.93","article-title":"Inherited calcium channelopathies in the pathophysiology of arrhythmias","volume":"9","author":"Venetucci","year":"2012","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cjca.2026.01.003_bib24","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/CIRCRESAHA.117.310882","article-title":"Allele-specific silencing of mutant mrna rescues ultrastructural and arrhythmic phenotype in mice carriers of the R4496C mutation in the ryanodine receptor gene (RYR2)","volume":"121","author":"Bongianino","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2026.01.003_bib25","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1161\/CIRCRESAHA.118.313369","article-title":"In vivo Ryr2 editing corrects catecholaminergic polymorphic ventricular tachycardia","volume":"123","author":"Pan","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2026.01.003_bib26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.20517\/jca.2023.42","article-title":"Long-term efficacy and safety of cardiac genome editing for catecholaminergic polymorphic ventricular tachycardia","volume":"4","author":"Moore","year":"2024","journal-title":"J Cardiovasc Aging"},{"key":"10.1016\/j.cjca.2026.01.003_bib27","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1161\/HYPERTENSIONAHA.111.173500","article-title":"Ryanodine receptor type 2 is required for the development of pressure overload-induced cardiac hypertrophy","volume":"58","author":"Zou","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2026.01.003_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba7287","article-title":"Cardiac ryanodine receptor calcium release deficiency syndrome","volume":"13","author":"Sun","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cjca.2026.01.003_bib29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s10038-020-0738-6","article-title":"Classification and correlation of RYR2 missense variants in individuals with catecholaminergic polymorphic ventricular tachycardia reveals phenotypic relationships","volume":"65","author":"Olubando","year":"2020","journal-title":"J Hum Genet"},{"key":"10.1016\/j.cjca.2026.01.003_bib30","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/FJC.0b013e3181a25078","article-title":"Calcium\/calmodulin-dependent kinase II regulation of cardiac ion channels","volume":"54","author":"Bers","year":"2009","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2026.01.003_bib31","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.yjmcc.2010.10.001","article-title":"Calmodulin kinase II inhibition prevents arrhythmias in RyR2R4496C+\/\u2212 mice with catecholaminergic polymorphic ventricular tachycardia","volume":"50","author":"Liu","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.cjca.2026.01.003_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.369","article-title":"CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia","volume":"4","author":"Di Pasquale","year":"2013","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.cjca.2026.01.003_bib33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fphar.2014.00021","article-title":"CaMKII inhibitors: from research tools to therapeutic agents","volume":"5","author":"Pellicena","year":"2014","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cjca.2026.01.003_bib34","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-pharmtox-051421-111814","article-title":"CaMKII as a therapeutic target in cardiovascular disease","volume":"63","author":"Reyes Gaido","year":"2023","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.cjca.2026.01.003_bib35","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.118.038514","article-title":"Gene Therapy for catecholaminergic polymorphic ventricular tachycardia by inhibition of Ca2+\/calmodulin-dependent kinase II","volume":"140","author":"Bezzerides","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.003_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.644630","article-title":"CaMKII\u03b4 splice variants in the healthy and diseased heart","volume":"9","author":"Duran","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.cjca.2026.01.003_bib37","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.008155","article-title":"Gene transfer of engineered calmodulin alleviates ventricular arrhythmias in a calsequestrin-associated mouse model of catecholaminergic polymorphic ventricular tachycardia","volume":"7","author":"Liu","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjca.2026.01.003_bib38","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1161\/CIRCRESAHA.117.310355","article-title":"Calcium signaling and transcriptional regulation in cardiomyocytes","volume":"121","author":"Dewenter","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2026.01.003_bib39","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1161\/CIRCRESAHA.120.318429","article-title":"Ca2+-CaM dependent inactivation of RyR2 underlies Ca2+ alternans in intact heart","volume":"128","author":"Wei","year":"2021","journal-title":"Circ Res"},{"issue":"suppl 2","key":"10.1016\/j.cjca.2026.01.003_bib40","article-title":"Overexpression of cardiac calsequestrin as a novel gene-therapy approach to treat CPVT1: in silico and in vivo proves of principle","volume":"44","author":"Santiago Castillo","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.01.003_bib41","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1172\/JCI1362","article-title":"Regulation of Ca2+ signaling in transgenic mouse cardiac myocytes overexpressing calsequestrin","volume":"101","author":"Jones","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cjca.2026.01.003_bib42","doi-asserted-by":"crossref","first-page":"28470","DOI":"10.1074\/jbc.273.43.28470","article-title":"Cardiac-specific overexpression of mouse cardiac calsequestrin is associated with depressed cardiovascular function and hypertrophy in transgenic mice","volume":"273","author":"Sato","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cjca.2026.01.003_bib44","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1161\/CIRCRESAHA.111.263939","article-title":"Viral gene transfer rescues arrhythmogenic phenotype and ultrastructural abnormalities in adult calsequestrin-null mice with inherited arrhythmias","volume":"110","author":"Denegri","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2026.01.003_bib45","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1161\/CIRCULATIONAHA.113.006901","article-title":"Single delivery of an adeno-associated viral construct to transfer the CASQ2 gene to knock-in mice affected by catecholaminergic polymorphic ventricular tachycardia is able to cure the disease from birth to advanced age","volume":"129","author":"Denegri","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.003_bib46","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.hrthm.2017.03.025","article-title":"Viral delivered gene therapy to treat catecholaminergic polymorphic ventricular tachycardia (CPVT2) in mouse models","volume":"14","author":"Kurtzwald-Josefson","year":"2017","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2026.01.003_bib47","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1161\/CIRCULATIONAHA.120.045723","article-title":"An international multicenter evaluation of inheritance patterns, arrhythmic risks, and underlying mechanisms of CASQ2-catecholaminergic polymorphic ventricular tachycardia","volume":"142","author":"Ng","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.003_bib48","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jacep.2022.02.017","article-title":"Congenital long QT syndrome","volume":"8","author":"Krahn","year":"2022","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.cjca.2026.01.003_bib49","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/europace\/euac114","article-title":"European Society of Cardiology quality indicators for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"25","author":"Aktaa","year":"2023","journal-title":"Europace"},{"key":"10.1016\/j.cjca.2026.01.003_bib50","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euad180","article-title":"From gene-discovery to gene-tailored clinical management: 25 years of research in channelopathies and cardiomyopathies","volume":"25","author":"Crotti","year":"2023","journal-title":"Europace"},{"key":"10.1016\/j.cjca.2026.01.003_bib51","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/eurheartj\/eht067","article-title":"Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes","volume":"35","author":"Matsa","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.01.003_bib52","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.3390\/ijms23074053","article-title":"shRNAs targeting a common KCNQ1 variant could alleviate long-QT1 disease severity by inhibiting a mutant allele","volume":"23","author":"C\u00f3cera-Ortega","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cjca.2026.01.003_bib53","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.hrthm.2012.09.124","article-title":"RNA interference targeting E637K mutation rescues hERG channel currents and restores its kinetic properties","volume":"10","author":"Lu","year":"2013","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2026.01.003_bib54","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1161\/CIRCULATIONAHA.123.065624","article-title":"In vivo base editing of Scn5a rescues type 3 long QT syndrome in mice","volume":"149","author":"Qi","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.003_bib55","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.122.003719","article-title":"Suppression and replacement gene therapy for KCNH2-mediated arrhythmias","volume":"15","author":"Bains","year":"2022","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.cjca.2026.01.003_bib56","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1093\/eurheartj\/ehae476","article-title":"KCNQ1 suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome","volume":"45","author":"Bains","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.01.003_bib57","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/eurheartj\/ehaf660","article-title":"AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome","volume":"47","author":"Nimani","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.01.003_bib58","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1161\/CIRCULATIONAHA.112.001216","article-title":"Calmodulin mutations associated with recurrent cardiac arrest in infants","volume":"127","author":"Crotti","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.003_bib59","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1093\/eurheartj\/ehad418","article-title":"Clinical presentation of calmodulin mutations: the International Calmodulinopathy Registry","volume":"44","author":"Crotti","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.01.003_bib60","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ajhg.2012.08.015","article-title":"Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death","volume":"91","author":"Nyegaard","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.cjca.2026.01.003_bib61","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/CIRCRESAHA.116.309283","article-title":"A precision medicine approach to the rescue of function on malignant calmodulinopathic long-QT syndrome","volume":"120","author":"Limpitikul","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2026.01.003_bib62","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1038\/nprot.2013.132","article-title":"CRISPR interference (CRISPRi) for sequence-specific control of gene expression","volume":"8","author":"Larson","year":"2013","journal-title":"Nat Protoc"},{"key":"10.1016\/j.cjca.2026.01.003_bib63","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.123.012036","article-title":"Single construct suppression and replacement gene therapy for the treatment of all CALM1-, CALM2-, and CALM3-mediated arrhythmia disorders","volume":"17","author":"Hamrick","year":"2024","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.cjca.2026.01.003_bib64","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41588-021-01007-6","article-title":"Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility","volume":"54","author":"Barc","year":"2022","journal-title":"Nat Genet"},{"key":"10.1016\/j.cjca.2026.01.003_bib65","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1161\/CIRCEP.115.003109","article-title":"Management of Brugada syndrome: thirty-three-year experience using electrophysiologically guided therapy with class 1A antiarrhythmic drugs","volume":"8","author":"Belhassen","year":"2015","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.cjca.2026.01.003_bib66","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1161\/CIRCULATIONAHA.122.063367","article-title":"Long-term outcomes of brugada substrate ablation: a report from BRAVO (Brugada Ablation of VF Substrate Ongoing Multicenter Registry)","volume":"147","author":"Nademanee","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.003_bib67","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/cvr\/cvae207","article-title":"Gene therapy for cardiac diseases: methods, challenges, and future directions","volume":"120","author":"Grisorio","year":"2024","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cjca.2026.01.003_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf3136","article-title":"Gene therapy targeting protein trafficking regulator MOG1 in mouse models of Brugada syndrome, arrhythmias, and mild cardiomyopathy","volume":"14","author":"Yu","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cjca.2026.01.003_bib69","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/eurheartj\/ehaa1051","article-title":"Brugada syndrome and reduced right ventricular outflow tract conduction reserve: a final common pathway?","volume":"42","author":"Behr","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.01.003_bib70","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCULATIONAHA.121.054083","article-title":"Variant intronic enhancer controls SCN10A-short expression and heart conduction","volume":"144","author":"Man","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.003_bib71","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/ng.2712","article-title":"Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death","volume":"45","author":"Bezzina","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.cjca.2026.01.003_bib72","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ng.516","article-title":"Genetic variation in SCN10A influences cardiac conduction","volume":"42","author":"Chambers","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.cjca.2026.01.003_bib73","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/s41588-018-0133-9","article-title":"Multi-ethnic genome-wide association study for atrial fibrillation","volume":"50","author":"Roselli","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.cjca.2026.01.003_bib74","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/eurheartj\/ehaf053","article-title":"SCN10A-short gene therapy to restore conduction and protect against malignant cardiac arrhythmias","volume":"46","author":"Wang","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.01.003_bib75","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jacep.2021.12.002","article-title":"Arrhythmogenic right ventricular cardiomyopathy","volume":"8","author":"Krahn","year":"2022","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.cjca.2026.01.003_bib76","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41436-021-01233-7","article-title":"The genetic architecture of plakophilin 2 cardiomyopathy","volume":"23","author":"Dries","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.cjca.2026.01.003_bib77","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/s44161-023-00382-z","article-title":"Restoring PKP2 in arrhythmogenic cardiomyopathy","volume":"2","author":"Priori","year":"2023","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.cjca.2026.01.003_bib78","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s43856-024-00450-w","article-title":"AAV9:PKP2 improves heart function and survival in a Pkp2-deficient mouse model of arrhythmogenic right ventricular cardiomyopathy","volume":"4","author":"Wu","year":"2024","journal-title":"Commun Med (Lond)"},{"key":"10.1016\/j.cjca.2026.01.003_bib79","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s44161-023-00370-3","article-title":"Plakophilin 2 gene therapy prevents and rescues arrhythmogenic right ventricular cardiomyopathy in a mouse model harboring patient genetics","volume":"2","author":"Bradford","year":"2023","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.cjca.2026.01.003_bib80","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s44161-023-00378-9","article-title":"Therapeutic efficacy of AAV-mediated restoration of PKP2 in arrhythmogenic cardiomyopathy","volume":"2","author":"Kyriakopoulou","year":"2023","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.cjca.2026.01.003_bib81","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.123.004305","article-title":"AAV-mediated delivery of plakophilin-2a arrests progression of arrhythmogenic right ventricular cardiomyopathy in murine hearts: preclinical evidence supporting gene therapy in humans","volume":"17","author":"van Opbergen","year":"2024","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.cjca.2026.01.003_bib82","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41467-017-00127-0","article-title":"Plakophilin-2 is required for transcription of genes that control calcium cycling and cardiac rhythm","volume":"8","author":"Cerrone","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.cjca.2026.01.003_bib83","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41536-025-00401-6","article-title":"Preclinical efficacy and safety of AAVrh10-based plakophilin-2 gene therapy (LX2020) as a treatment for arrhythmogenic cardiomyopathy","volume":"10","author":"Zhang","year":"2025","journal-title":"NPJ Regen Med"},{"key":"10.1016\/j.cjca.2026.01.003_bib84","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1399-0004.2012.01919.x","article-title":"The natural history of a genetic subtype of arrhythmogenic right ventricular cardiomyopathy caused by a p.S358L mutation in TMEM43","volume":"83","author":"Hodgkinson","year":"2013","journal-title":"Clin Genet"},{"key":"10.1016\/j.cjca.2026.01.003_bib85","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.115.003589","article-title":"Long-term clinical outcome of arrhythmogenic right ventricular cardiomyopathy in individuals with a p.S358L mutation in TMEM43 following implantable cardioverter defibrillator therapy","volume":"9","author":"Hodgkinson","year":"2016","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.cjca.2026.01.003_bib86","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jacc.2004.08.068","article-title":"The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5)","volume":"45","author":"Hodgkinson","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2026.01.003_bib87","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/cvr\/cvaa300","article-title":"Haploinsufficiency of Tmem43 in cardiac myocytes activates the DNA damage response pathway leading to a late-onset senescence-associated pro-fibrotic cardiomyopathy","volume":"117","author":"Rouhi","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cjca.2026.01.003_bib88","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/CIRCULATIONAHA.119.040366","article-title":"Severe cardiac dysfunction and death caused by arrhythmogenic right ventricular cardiomyopathy type 5 are improved by inhibition of glycogen synthase kinase-3\u03b2","volume":"140","author":"Padr\u00f3n-Barthe","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.003_bib89","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/CIRCRESAHA.124.325848","article-title":"Overexpression of wild-type TMEM43 improves cardiac function in arrhythmogenic right ventricular cardiomyopathy type 5","volume":"136","author":"Lalaguna","year":"2025","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2026.01.003_bib90","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1073\/pnas.0510519103","article-title":"A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy","volume":"103","author":"Haghighi","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cjca.2026.01.003_bib91","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/eurjhf\/hfs119","article-title":"Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy","volume":"14","author":"van der Zwaag","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2026.01.003_bib92","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1093\/eurheartj\/ehad292","article-title":"A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers","volume":"44","author":"de Brouwer","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.01.003_bib93","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s12471-013-0401-3","article-title":"Recurrent and founder mutations in the Netherlands\u2014phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy","volume":"21","author":"van der Zwaag","year":"2013","journal-title":"Neth Heart J"},{"key":"10.1016\/j.cjca.2026.01.003_bib94","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s12471-018-1211-4","article-title":"Prevalence and cardiac phenotype of patients with a phospholamban mutation","volume":"27","author":"Hof","year":"2019","journal-title":"Neth Heart J"},{"key":"10.1016\/j.cjca.2026.01.003_bib95","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.jacc.2006.07.016","article-title":"Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy","volume":"48","author":"DeWitt","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2026.01.003_bib96","doi-asserted-by":"crossref","DOI":"10.1111\/apha.14082","article-title":"Early consequences of the phospholamban mutation PLN-R14del+\/\u2212 in a transgenic mouse model","volume":"240","author":"Maniezzi","year":"2024","journal-title":"Acta Physiol (Oxf)"},{"key":"10.1016\/j.cjca.2026.01.003_bib97","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jacbts.2024.02.017","article-title":"Reassessing the mechanisms of PLN-R14del Cardiomyopathy: from calcium dysregulation to S\/ER malformation","volume":"9","author":"Stege","year":"2024","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.cjca.2026.01.003_bib98","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1093\/cvr\/cvac021","article-title":"Gene editing reverses arrhythmia susceptibility in humanized PLN-R14del mice: modelling a European cardiomyopathy with global impact","volume":"118","author":"Dave","year":"2022","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cjca.2026.01.003_bib99","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1038\/s41467-021-25439-0","article-title":"Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy","volume":"12","author":"Grote Beverborg","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.cjca.2026.01.003_bib100","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1161\/CIRCRESAHA.123.323304","article-title":"DWORF extends life span in a PLN-R14del cardiomyopathy mouse model by reducing abnormal sarcoplasmic reticulum clusters","volume":"133","author":"Stege","year":"2023","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2026.01.003_bib101","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-physiol-021014-071622","article-title":"Mechanisms of ventricular arrhythmias: from molecular fluctuations to electrical turbulence","volume":"77","author":"Qu","year":"2015","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.cjca.2026.01.003_bib102","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.bpj.2010.06.042","article-title":"So little source, so much sink: requirements for afterdepolarizations to propagate in tissue","volume":"99","author":"Xie","year":"2010","journal-title":"Biophys J"},{"key":"10.1016\/j.cjca.2026.01.003_bib103","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.120.008420","article-title":"Stabilizer cell gene therapy: a less-is-more strategy to prevent cardiac arrhythmias","volume":"13","author":"Liu","year":"2020","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.cjca.2026.01.003_bib104","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.yjmcc.2013.10.018","article-title":"Cardiac fibrosis and arrhythmogenesis: the road to repair is paved with perils","volume":"70","author":"Nguyen","year":"2014","journal-title":"J Mol Cell Cardiol"},{"issue":"suppl 1","key":"10.1016\/j.cjca.2026.01.003_bib105","article-title":"Abstract 12241: Low-efficiency gene editing is capable of suppressing arrhythmogenesis in long QT syndrome type II: computer simulation study","volume":"148","author":"Navarrete-Welton","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.003_bib106","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41569-019-0179-0","article-title":"Animal models of arrhythmia: classic electrophysiology to genetically modified large animals","volume":"16","author":"Clauss","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cjca.2026.01.003_bib107","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/s44161-023-00393-w","article-title":"Unexpected impairment of INa underpins reentrant arrhythmias in a knock-in swine model of Timothy syndrome","volume":"2","author":"Porta-S\u00e1nchez","year":"2023","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.cjca.2026.01.003_bib108","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.hlc.2018.08.026","article-title":"Epidemiology of sudden cardiac death: global and regional perspectives","volume":"28","author":"Wong","year":"2019","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.cjca.2026.01.003_bib109","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1161\/CIRCRESAHA.120.315855","article-title":"Gene therapy for the heart lessons learned and future perspectives","volume":"126","author":"Cannat\u00e0","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2026.01.003_bib110","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nm1503","article-title":"Molecular ablation of ventricular tachycardia after myocardial infarction","volume":"12","author":"Sasano","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2026.01.003_bib111","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/CIRCULATIONAHA.108.809301","article-title":"Epicardial border zone overexpression of skeletal muscle sodium channel SkM1 normalizes activation, preserves conduction, and suppresses ventricular arrhythmia: an in silico, in vivo, in vitro study","volume":"119","author":"Lau","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.003_bib112","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/cvr\/cvq284","article-title":"Expression of skeletal muscle sodium channel (Nav1.4) or connexin32 prevents reperfusion arrhythmias in murine heart","volume":"89","author":"Anyukhovsky","year":"2011","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cjca.2026.01.003_bib113","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009598","article-title":"Primary effect of SERCA 2a gene transfer on conduction reserve in chronic myocardial infarction","volume":"7","author":"Motloch","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjca.2026.01.003_bib114","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ymthe.2022.11.017","article-title":"Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting","volume":"31","author":"Anttila","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.cjca.2026.01.003_bib115","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.109.911156","article-title":"Selective molecular potassium channel blockade prevents atrial fibrillation","volume":"121","author":"Amit","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.003_bib116","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/cvr\/cvr209","article-title":"Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model","volume":"92","author":"Bikou","year":"2011","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cjca.2026.01.003_bib117","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/CIRCULATIONAHA.111.053272","article-title":"Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation","volume":"125","author":"Igarashi","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.003_bib118","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.119.007465","article-title":"Genetic ablation of TASK-1 (Tandem of P Domains in a Weak Inward Rectifying K+ Channel\u2013Related Acid-Sensitive K+ Channel 1) (K2P3.1) K+ channels suppresses atrial fibrillation and prevents electrical remodeling","volume":"12","author":"Schmidt","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.cjca.2026.01.003_bib119","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.yjmcc.2024.09.004","article-title":"Gene therapy for atrial fibrillation","volume":"196","author":"Mo","year":"2024","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.cjca.2026.01.003_bib120","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-020-0188-7","article-title":"Inherited cardiac arrhythmias","volume":"6","author":"Schwartz","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.cjca.2026.01.003_bib121","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jacep.2021.12.001","article-title":"Brugada Syndrome","volume":"8","author":"Krahn","year":"2022","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.cjca.2026.01.003_bib122","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1161\/CIRCULATIONAHA.124.072340","article-title":"Modified mRNA Treatment restores cardiac function in desmocollin-2\u2013deficient mouse models of arrhythmogenic right ventricular cardiomyopathy","volume":"151","author":"Zou","year":"2025","journal-title":"Circulation"},{"issue":"suppl 1","key":"10.1016\/j.cjca.2026.01.003_bib123","article-title":"Connexin-43 gene therapy targets desmosomal gene expression to rescue cardiac end-stage deficits in mouse and human models of arrhythmogenic cardiomyopathy [abstract]","volume":"137","author":"Zhang","year":"2025","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2026.01.003_bib124","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1093\/eurheartj\/ehaf703","article-title":"CRISPR activation to repair electrocardiogram abnormalities caused by a FLNC truncating variant in mice","volume":"46","author":"Ca\u00f1as-Alvaro","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.01.003_bib125","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.hrthm.2023.03.287","article-title":"BS-452758-3 Suppression-replacement gene therapy for LMNA-mediated cardiomyopathies","volume":"20","author":"Gluscevic","year":"2023","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2026.01.003_bib126","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade1633","article-title":"Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy","volume":"14","author":"Nishiyama","year":"2022","journal-title":"Sci Transl Med"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X26000061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X26000061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:22:36Z","timestamp":1778815356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X26000061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":124,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0828282X26000061"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2026.01.003","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Gene Therapies for Inherited Arrhythmia Syndromes","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2026.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}